Floatz logo

Xanomeline

Cognitive Impairment

European Group for Research In SchizophreniaSmall moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

149 Active assets in the Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Metformin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

Xanomeline is also rated in:

schizophreniaDormant
BBB
Indicative ·
76 / 100
View asset →
manic bipolar affective disorderDormant
B
Indicative ·
60 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →